Results 51 to 60 of about 89,027 (290)

Deformable nanocarriers for enhanced drug delivery and cancer therapy

open access: yesExploration
Recently, the field of nanomedicine has witnessed substantial advancements in the development of nanocarriers for targeted drug delivery, emerges as promising platforms to enhance therapeutic efficacy and minimize adverse effects associated with ...
Ziyang Cao, Jing Liu, Xianzhu Yang
doaj   +1 more source

Exploiting recent trends for the synthesis and surface functionalization of mesoporous silica nanoparticles towards biomedical applications

open access: yesInternational Journal of Pharmaceutics: X, 2022
Rapid progress in developing multifunctional nanocarriers for drug delivery has been observed in recent years. Inorganic mesoporous silica nanocarriers (MSNs), emerged as an ideal candidate for gene/drug delivery with distinctive morphological features ...
Bazla Siddiqui   +5 more
doaj   +1 more source

VIVID: A qPCR‐Based Platform for Sensitive and Quantitative In Vivo Tracking of Extracellular Vesicles

open access: yesAdvanced Functional Materials, EarlyView.
This study introduces VIVID (Vesicle In Vivo Identification using DNA), a qPCR‐based platform that tracks PCR‐amplifiable DNA tags loaded in the EVs for accurate and quantifiable EV biodistribution in vivo. ABSTRACT Extracellular vesicles (EVs) represent promising carriers for nucleic acid therapeutics, offering advantages over synthetic nanoparticles ...
Oscar Boyadjian   +5 more
wiley   +1 more source

l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells [PDF]

open access: yes, 2018
Nanoparticles and macromolecular carriers have been widely used to increase the efficacy of chemotherapeutics, largely through passive accumulation provided by their enhanced permeability and retention effect.
Bremner, David H   +8 more
core   +2 more sources

Biomimetic Nanovaccine Integrating Dendritic Cell Exosomes with Tumor Cell Membranes for Sustained Prophylaxis Against Glioblastoma

open access: yesAdvanced Functional Materials, EarlyView.
We have developed DEX/GM, an all‐natural, personalizable hybrid vaccine designed by coating dendritic cell‐derived exosomes (DEX) onto tumor cell membranes (GM) for sustained prophylaxis against glioblastoma (GBM). ABSTRACT Glioblastoma (GBM), one of the most aggressive and lethal brain tumors, remains incurable with a poor clinical prognosis.
Shanshan Li   +6 more
wiley   +1 more source

Poly(triazolyl methacrylate) glycopolymers as potential targeted unimolecular nanocarriers [PDF]

open access: yes, 2019
© The Royal Society of Chemistry 2019.Synthetic glycopolymers are increasingly investigated as multivalent ligands for a range of biological and biomedical applications.
Fernandez-Trillo, F.   +12 more
core   +4 more sources

Photo‐Controlled Antibacterial Drug Release From DASA‐Coated Silica Particles for Improved Treatment of Wound Infections

open access: yesAdvanced Functional Materials, EarlyView.
Synthesis and characterization of light‐responsive donor–acceptor Stenhouse adducts (DASA)‐coated chlorhexidine‐loaded silica nanoparticles. Such a controllable drug‐delivery system enables the release of the antimicrobial drug on demand and in consecutive cycles, thereby maintaining the concentration within the therapeutic window.
Michèle Clerc   +9 more
wiley   +1 more source

Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium

open access: yesJournal of Nanobiotechnology
Endothelial cells (ECs) are pivotal in maintaining vascular health, regulating hemodynamics, and modulating inflammatory responses. Nanocarriers hold transformative potential for precise drug delivery within the vascular system, particularly targeting ...
Xiuxiu Cong   +5 more
doaj   +1 more source

Dextran-based Nanocarriers as Efficient Media Delivery Vehicles to Cell Production Bioreactors

open access: yesNano Biomedicine and Engineering, 2010
Decreasing the volume of media required to maintain cell viability not only reduces contamination of bioreactors from the upstream process, but may contribute to cost-containment measures in the biopharmaceutical industry.
Edmund Anton   +3 more
doaj   +1 more source

Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable

open access: yesPharmaceutics, 2022
Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood–brain barrier (BBB) prevents chemotherapeutic chemicals from ...
Amir Barzegar Behrooz   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy